I see it everywhere: Seeking alpha, yahoo, and iH

I see it everywhere: Seeking alpha, yahoo, and iHub—see example below. All kinds of people think they have the solution to fix Cydy. For example, they’re waisting money on videos—well at say $1000 per video that is $30,000. Now they just need to cut $50M more out, most of which is going towards the BLA. But how are you going to pay for it without raising money. So you pay to raise money towards paying for the BLA, or cash to pay people to raise money or work towards the BLA. With $200M, Cydy has got combo almost to BLA submission, and mono to phase 3 pivotal with the added bonus of GvHD and TNBC in phase 2, with possibly NASH, MS, and other cancers this year phase 2. It could take another $30M, depending on the number of people in the mono trial and it being successful to finish that. So, say $250M spent for mono and combo approval. How much do you think Pfizer spent on Maraviroc approval?

The other complaint is they are waisting time working on this or that instead of getting drug approval. So I wanted to address it, to show almost all their resources are going towards approval, even when they are talking about NASH or whatever. What are they spending on NASH which will possibly get them to phase 2? Was it $30k? How much value does that add to have a phase 2 development for NASH? Or say leverage in a buyout or licensing discussion.

Yahoo https://finance.yahoo.com/quote/CYDY/community?p=CYDY

Quote:

---

This is sad because the company could possibly survive if the officers eliminate lavish salaries such #$%$ one million for the President. Also eliminate testing on multiple indications such as breast cancer and host vs graft etc and instead focus on one indication that apparently has supportive data such as HIV suppresion. I have followed this company for many years and have been in and out and still have some shares. I hope the company will reduce their spending so they can achieve FDA indicaton for their CCC5 inhibitor drug. I have read numerous messages on several boards and no where have I seen one realistic expression about the out of control spending that is continuing despite the burgeoning liabilities. I just hope that investors start pressing for budgetary restraints.

---